The authors thank Alberto Enrico Maraola and colleagues for careful reading of their seminar on community-acquired pneumonia. They highlighted an important point: expanding therapeutic options against methicillin-resistant Staphylococcus aureus (MRSA). However, this increase in treatment options does not change the basic principle. Empirical coverage of MRSA should be reserved for patients with clearly defined risk factors. Also for patients with confirmed MRSA infection.